Literature DB >> 15115867

Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries.

R T Bennett1, R D Jones, A H Morice, C F C Smith, M E Cowen.   

Abstract

BACKGROUND: Urotensin II (UII) has been identified as a ligand for the orphan receptor GPR14 through which it elicits potent vasoconstriction in humans and non-human primates. The pulmonary vasculature is particularly sensitive; human UII (hUII) exhibits a potency 28 times that of endothelin (ET)-1 in isolated pulmonary arteries obtained from cynomolgus monkeys. However, hUII induced vasoconstriction in isolated human intralobar pulmonary arteries is variable, possibly as a result of location dependent differences in receptor density or because it is only uncovered by disease dependent endothelial dysfunction.
METHODS: The vasoactivity of both hUII and gobi UII (gUII) in comparison with ET-1 and ET-3 was studied in isolated perfused lung preparations (n = 14) and isolated intralobar pulmonary arteries (n = 40, mean diameter 548 (27) microm) obtained from 17 men of mean (SE) age 67 (2) years and eight women of mean (SE) age 65 (3) years with a variety of vascular diseases.
RESULTS: ET-1 (10 pM-100 nM) and ET-3 (10 pM-30 nM) elicited vasoconstriction in the lung preparations, inducing comparable increases in pulmonary arterial pressure of 24.8 (4.5) mm Hg and 14.5 (4.9) mm Hg, respectively, at 30 nM (p = 0.13). Similarly, ET-1 (10 pM-300 nM) and ET-3 (10 pM-100 nM) caused marked vasoconstriction in isolated pulmonary arteries, inducing maximal changes in tension of 4.36 (0.26) mN/mm and 1.54 (0.44) mN/mm, respectively, generating -logEC(50) values of 7.67 (0.04) M and 8.08 (0.07) M, respectively (both p<0.05). However, neither hUII nor gUII (both 10 pM-1 micro M) had any vasoactive effect in either preparation.
CONCLUSION: UII does not induce vasoconstriction in isolated human pulmonary arterial or lung preparations and is therefore unlikely to be involved in the control of pulmonary vascular tone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115867      PMCID: PMC1747004          DOI: 10.1136/thx.2003.011197

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  21 in total

1.  Human urotensin II mediates vasoconstriction via an increase in inositol phosphates.

Authors:  O Saetrum Opgaard; H Nothacker; F J Ehlert; D N Krause
Journal:  Eur J Pharmacol       Date:  2000-10-13       Impact factor: 4.432

2.  Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.

Authors:  S A Douglas; A C Sulpizio; V Piercy; H M Sarau; R S Ames; N V Aiyar; E H Ohlstein; R N Willette
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries.

Authors:  A Stirrat; M Gallagher; S A Douglas; E H Ohlstein; C Berry; A Kirk; M Richardson; M R MacLean
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-02       Impact factor: 4.733

4.  Effects of urotensin II in human arteries and veins of varying caliber.

Authors:  C Hillier; C Berry; M C Petrie; P J O'Dwyer; C Hamilton; A Brown; J McMurray
Journal:  Circulation       Date:  2001-03-13       Impact factor: 29.690

5.  Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat.

Authors:  M R MacLean; D Alexander; A Stirrat; M Gallagher; S A Douglas; E H Ohlstein; I Morecroft; K Polland
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

6.  Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14.

Authors:  Q Liu; S S Pong; Z Zeng; Q Zhang; A D Howard; D L Williams; M Davidoff; R Wang; C P Austin; T P McDonald; C Bai; S R George; J F Evans; C T Caskey
Journal:  Biochem Biophys Res Commun       Date:  1999-12-09       Impact factor: 3.575

7.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.

Authors:  R S Ames; H M Sarau; J K Chambers; R N Willette; N V Aiyar; A M Romanic; C S Louden; J J Foley; C F Sauermelch; R W Coatney; Z Ao; J Disa; S D Holmes; J M Stadel; J D Martin; W S Liu; G I Glover; S Wilson; D E McNulty; C E Ellis; N A Elshourbagy; U Shabon; J J Trill; D W Hay; E H Ohlstein; D J Bergsma; S A Douglas
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

8.  The effect of the endothelin ET(A) receptor antagonist CI-1020 on hypoxic pulmonary vasoconstriction.

Authors:  R D Jones; J C Wanstall; A Gambino; A H Morice
Journal:  Eur J Pharmacol       Date:  1999-06-25       Impact factor: 4.432

9.  Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase.

Authors:  V Sauzeau; E Le Mellionnec; J Bertoglio; E Scalbert; P Pacaud; G Loirand
Journal:  Circ Res       Date:  2001-06-08       Impact factor: 17.367

10.  Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

View more
  5 in total

Review 1.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 2.  The ex vivo human lung: research value for translational science.

Authors:  James T Ross; Nicolas Nesseler; Jae-Woo Lee; Lorraine B Ware; Michael A Matthay
Journal:  JCI Insight       Date:  2019-06-06

3.  State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells.

Authors:  Eugen Brailoiu; Xiaohua Jiang; G Cristina Brailoiu; Jun Yang; Jaw Kang Chang; Hong Wang; Nae J Dun
Journal:  Peptides       Date:  2008-01-31       Impact factor: 3.750

4.  Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels.

Authors:  Elif Oral; Zekai Halici; Irfan Cinar; Elif Ozcan; Zerrin Kutlu
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-05-31       Impact factor: 2.582

5.  Characterization of the vasodilatory action of testosterone in the human pulmonary circulation.

Authors:  Alyson M Smith; Robert T Bennett; T Hugh Jones; Mike E Cowen; Kevin S Channer; Richard D Jones
Journal:  Vasc Health Risk Manag       Date:  2008
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.